MEMPHIS, Tenn., July 15, 2015 (GLOBE NEWSWIRE) -- Wright Medical Group, Inc. (Nasdaq:WMGI) today announced that it will highlight recent innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2015 Annual Meeting taking place at the Long Beach Convention Center in Long Beach, California, from July 15-18, 2015.
Wright will feature its full range of foot and ankle reconstructive solutions at exhibit booth #231, including the following products and recent innovations:
- INFINITY® and INBONE® II Total Ankle Replacement (TAR) Systems – The lower profile design and straightforward surgical approach of the INFINITY® TAR system can expand access to less complicated primary cases and is an important addition to the continuum of care for end-stage ankle arthritis patients. Several product line extensions for the INBONE® II TAR system will be featured, including the availability of a smaller size talar dome to address patients with small anatomy who would benefit from a smaller talar dome option as well as a revision poly insert and uncoated tibia stems to provide surgeons with more options.
- PROPHECY® Pre-Operative Navigation Alignment Guides – The PROPHECY® Pre-Operative Navigation Alignment Technology utilizes computed tomography (CT) scans to create patient-specific ankle alignment guides that facilitate the surgeons’ ability to precisely size, place and align the INFINITY® and INBONE® TAR components during surgery.
- SALVATION® Limb Salvage Portfolio – The SALVATION® Limb Salvage Portfolio includes the SALVATION® Fusion Bolts and Beams, the SALVATION® 3Di Plating System and the SALVATION® External Fixation System, which can be used individually or together for limb salvage cases.
Robert Palmisano, president and chief executive officer, stated, “We have continued to expand our broad product portfolio to further extend our leadership position in foot and ankle. The INFINITY and INBONE total ankle replacement systems and PROPHECY technology offer surgeons a full continuum of care for end-stage ankle arthritis patients and continue to be important catalysts in the ongoing market conversion from fusion procedures to total ankle replacement. In addition, our new SALVATION limb salvage portfolio is the first comprehensive solution for Charcot arthropathy and advanced midfoot reconstruction procedures. This provides us with a unique future opportunity to address a large and growing patient population who are at high-risk of peripheral neuropathies. We are continuing to collect initial physician testing data for our SALVATION product portfolio in preparation for a future product launch.”
More information on Wright’s foot and ankle products can be found here and in Wright’s sponsored section on WebMD.
Internet Posting of Information
Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wmt.com. Wright encourages investors and potential investors to consult its website regularly for important information about the company.
About Wright Medical
Wright Medical Group, Inc. is a specialty orthopaedic company that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company is the recognized leader of surgical solutions for the foot and ankle market, one of the fastest growing segments in medical technology, and markets its products in over 60 countries worldwide. For more information, visit Wright Medical.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements in this press release include, but are not limited to, statements about the potential for market acceptance and clinical performance of our products. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that competitive products achieve greater clinical success or market acceptance than our products, or that our products, for whatever reason, are less successful or clinically effective than presently anticipated, and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K, filed with the SEC on February 26, 2015, as supplemented by our subsequent Quarterly Reports on Form 10-Q and other information filed with the SEC. Investors should not place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.